Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of the formula (I)



(I)

wherein

R_1 is an unsubstituted phenyl radical and lower alkoxy-substituted phenyl, wherein the lower alkoxy substituent is at the position meta or para to the bond to the pyrimidine ring, or a heteroaryl radical selected from a thiazolyl, pyrazinyl, pyrimidinyl or 6-substituted-3-pyridyl radical; and

R_2 is a phenyl radical that is substituted in at least the 3-position by fluorine, halo-lower alkyl, halo-lower alkoxy, or halo-lower alkylthio;

or an N-oxide or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) A compound of formula I wherein R_1 is selected from a phenyl radical, a thiazolyl radical, a pyrazinyl radical, a pyrimidinyl radical or a 6-substituted-3-pyridyl radical.

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) A compound of claim 1 wherein R_1 is a phenyl, 2-thiazolyl, 2-pyrazinyl, 5-pyrimidinyl or 6-substituted-3-pyridyl radical.

6. (Original) A compound of claim 5 wherein R_2 is phenyl that is substituted in at least the 3-position by fluorine, halo-lower alkyl, halo-lower alkoxy, or halo-lower alkylthio.

7. (Currently Amended) A compound of claim 1 of formula II



(II)

wherein

n is 0, 1 or 2;

A_1, A_2 and A_3 are C<u>H</u>, or A_1 and A_2 are C<u>H</u> and A_3 is N, or A_1 and A_3 are N and A_2 is C<u>H</u>, or A_1 is C<u>H</u> and A_2 and A_3 are N;

R_3 is $-NR_5R_6$, halogen, $-O-R_8$, $-S-R_8$, or lower alkyl which is unsubstituted or substituted by halogen, hydroxy, lower alkoxy, $-NR_7R_8$, or a heteroaryl or heterocyclic radical attached at a ring carbon;

R_4 is amino, mono- or di-lower alkyl-substituted amino, wherein the alkyl groups are unsubstituted or substituted by halogen or lower alkoxy; halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, hydroxy, lower alkanoyl, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, mercapto, lower alkylthio or halo-lower alkylthio;

R_5, R_6, R_7 and R_8 are independently hydrogen, a heteroaryl or heterocyclic radical attached at a ring carbon, lower alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-lower alkylene, lower alkyl which is substituted by hydroxy, lower alkoxy, a heteroaryl radical, a heterocyclic radical, amino, mono- or di-lower alkyl amino or R_5 and R_6 or R_7 and R_8 together with the nitrogen form a heteroaromatic or heterocyclic radical;

R_8 is a heterocyclic radical, a heteroaromatic radical, heteroaryl-lower-alkylene, heterocyclic-lower-alkylene, lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy or $-NR_7R_8$;
or an N-oxide or a pharmaceutically acceptable salt thereof.

8. (Currently Amended) A compound of claim 7 wherein $R_{[[2]]4}$ is ~~phenyl that is substituted~~ in at least the 3-position and is represented by halogen, mono- or di-lower alkyl-substituted amino; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; lower alkylthio; or halo-lower alkylthio.

9. (Original) A compound of claim 1 of formula (III)



(III)

wherein
n is 0, 1 or 2;
R_3 is $-NR_5R_6$, halogen, $-O-R_8$, $-S-R_8$, or lower alkyl which is unsubstituted or substituted by halogen, hydroxy, lower alkoxy, $-NR_7R_8$, or a heteroaryl or heterocyclic radical attached at a ring carbon;
R_4 is amino, mono- or di-lower alkyl-substituted amino, wherein the alkyl groups are unsubstituted or substituted by halogen or lower alkoxy; halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, hydroxy, lower alkanoyl, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, mercapto, lower alkylthio or halo-lower alkylthio;
R_5, R_6, R_7 and R_8 are independently hydrogen, a heteroaryl or heterocyclic radical attached at a ring carbon, lower alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-lower alkylene, lower alkyl which is substituted by hydroxy, lower alkoxy, a heteroaryl radical, a heterocyclic radical, amino, mono- or di-lower alkyl amino or R_5 and R_6 or R_7 and R_8 together with the nitrogen form a heteroaromatic or heterocyclic radical;

R_8 is a heterocyclic radical, a heteroaromatic radical, heteroaryl-lower-alkylene, heterocyclic-lower-alkylene, lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy or $-NR_7R_8$;
or an N-oxide or a pharmaceutically acceptable salt thereof.

10. (Original) A compound of claim 9 wherein R_4 is halogen, mono- or di-lower alkyl-substituted amino; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; lower alkylthio; or halo-lower alkylthio.

11. (Currently Amended) A compound of claim 10 wherein R_4 is [[phenyl]] halo-lower alkyl, halo-lower alkoxy or halo-lower alkylthio.

12. (Original) A compound of claim 9 wherein R_4 is trifluoromethyl.

13. (Original) A compound of claim 9 wherein R_3 is $-NR_5R_6$ and one of R_5 and R_6 is lower alkyl substituted by $-NR_7R_8$ and R_7 and R_8 together with the nitrogen form a heteroaromatic or heterocyclic radical.

14. (Currently Amended) A compound of claim 13 wherein the heteroaromatic or heterocyclic radical is selected from morphilino, thiomorphilino, piperazinyl, piperidinyl, and 6-substituted-3-pyridyl.

15. (Currently Amended) A compound of claim 9 wherein $-NR_5R_6$ is a heteroaryl or heterocyclic radical.

16. (Original) A compound of claim 15 wherein $-NR_5R_6$ is a heteroaryl or heterocyclic radical selected from piperazinyl, 4-methylpiperazinyl, piperidinyl, 4-hydroxypiperidinyl, morphilino and thiomorphilino.

17. (Original) A compound of claim 9 wherein R_8 is lower alkyl, lower alkyl substituted by hydroxy or lower alkoxy, or a heteroaryl or heterocyclic radical.

18. (Original) A compound of claim 9 of formula (IIIa)



(IIIa)

19. (Original) A compound of claim 9 of formula IIIb



(IIIb)

20. (Original) A compound of claim 7 of formula IV



(IV)

wherein

n is 0, 1 or 2;

R_3 is hydrogen, $-NR_5R_6$, halogen, $-O-R_8$, $-S-R_8$, or lower alkyl which is unsubstituted or substituted by halogen, hydroxy, lower alkoxy, $-NR_7R_8$, or a heteroaryl or heterocyclic radical attached at a ring carbon;

R_4 is amino, mono- or di-lower alkyl-substituted amino, wherein the alkyl groups are unsubstituted or substituted by halogen or lower alkoxy; halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, hydroxy, lower alkanoyl, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, mercapto, lower alkylthio or halo-lower alkylthio;

R_5, R_6, R_7 and R_8 are independently hydrogen, a heteroaryl or heterocyclic radical attached at a ring carbon, lower alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-lower alkylene, lower alkyl which is substituted by hydroxy, lower alkoxy, a heteroaryl radical, a heterocyclic radical, amino, mono- or di-lower alkyl amino or R_5 and R_6 or R_7 and R_8 together with the nitrogen form a heteroaromatic or heterocyclic radical;

R_8 is a heterocyclic radical, a heteroaromatic radical, heteroaryl-lower-alkylene, heterocyclic-lower-alkylene, lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy or $-NR_7R_8$;

or a pharmaceutically acceptable salt thereof.

21. (Original) A compound of claim 20 wherein R_4 is halogen, mono- or di-lower alkyl-substituted amino; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; lower alkylthio; or halo-lower alkylthio.

22. (Original) A compound of claim 21 wherein at least one R4 substituent is in the meta position relative to the carbonyl.

23. (Currently Amended) A compound of claim 7 of the formula (V)



(V)

wherein

n is 0, 1 or 2;

R_3 is ~~NR_5R_6, halogen, O-R_8, S-R_8, or lower alkyl which is unsubstituted or substituted by halogen, hydroxyl,~~ lower alkoxy~~, $-NR_7R_8$, or a heteroaryl or heterocyclic radic al attached at a ring carbon~~;

R_4 is amino, mono- or di-lower alkyl-substituted amino, wherein the alkyl groups are unsubstituted or substituted by halogen or lower alkoxy; halogen, lower alkyl, halo-lower alkyl, lower alkoxy, halo-lower alkoxy, hydroxy, lower alkanoyl, carbamoyl, N-mono- or N,N-di-substituted carbamoyl, mercapto, lower alkylthio or halo-lower alkylthio;

R_5, R_6, R_7 and R_8 are independently hydrogen, a heteroaryl or heterocyclic radical attached at a ring carbon, lower alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-lower alkylene, lower alkyl which is substituted by hydroxy, lower alkoxy, a heteroaryl radical, a heterocyclic radical, amino, mono- or di-lower alkyl amino or R_5 and R_6 or R_7 and R_8 together with the nitrogen form a heteroaromatic or heterocyclic radical;

R_8 is a heterocyclic radical, a heteroaromatic radical, heteroaryl-lower-alkylene, heterocyclic-lower-alkylene, lower alkyl or lower alkyl which is substituted by hydroxy, lower alkoxy or $-NR_7R_8$;

or a pharmaceutically acceptable salt thereof.

24. (Original) A compound of claim 23 wherein R_4 is halogen, mono- or di-lower alkyl-substituted amino; lower alkyl; halo-lower alkyl; lower alkoxy; halo-lower alkoxy; lower alkylthio; or halo-lower alkylthio.

25. (Original) A compound of claim 24 wherein at least one R4 substituent is in the meta position relative to the carbonyl.

26. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (I) according to claim 1.

27. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (II) according to claim 7.

28. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (III) according to claim 9.

[[28]]29. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (IIIb) according to claim 19.

[[29]]30. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (IV) according to claim 20.

[[30]]31. (Currently Amended) A method of treating a patient having a disease characterized by excessive signaling through the MAP kinase signaling pathway wherein the disease is melanoma, which comprises administering to the patient an effective RAF kinase inhibiting amount of a compound of formula (V) according to claim 23.

[[31]]32. (Currently Amended) A process for the preparation of a compound of the formula (I),



(I)

wherein

R_1 is a phenyl radical or a heteroaryl radical; and

R_2 is a phenyl radical;

or an N-oxide or a pharmaceutically acceptable salt thereof;

which process comprises preparing a compound of formula VIII by reacting a compound of formula VI with a compound of formula VII according to the following scheme



VI VII VIII

[[32]]33. (Cancelled)

[[33]]34. (Cancelled)

[[34]]35. (Cancelled)